{"title":"【临床病例:缬沙坦/苏比特里早期联用治疗高血压】。","authors":"N. G. Lozhkina, A. Spiridonov","doi":"10.18087/cardio.2022.5.n1977","DOIUrl":null,"url":null,"abstract":"Metabolic syndrome is a disease the World Health Organization has called a new pandemic of the 21st century. Arterial hypertension is one of the criteria for this diagnosis and a determinant of damage to major target organs. The present clinical case demonstrates an experience of treatment of arterial hypertension associated with metabolic syndrome with a valsartan/sacubitril molecular complex.","PeriodicalId":33976,"journal":{"name":"B''lgarska kardiologiia","volume":"5 1","pages":"72-74"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].\",\"authors\":\"N. G. Lozhkina, A. Spiridonov\",\"doi\":\"10.18087/cardio.2022.5.n1977\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metabolic syndrome is a disease the World Health Organization has called a new pandemic of the 21st century. Arterial hypertension is one of the criteria for this diagnosis and a determinant of damage to major target organs. The present clinical case demonstrates an experience of treatment of arterial hypertension associated with metabolic syndrome with a valsartan/sacubitril molecular complex.\",\"PeriodicalId\":33976,\"journal\":{\"name\":\"B''lgarska kardiologiia\",\"volume\":\"5 1\",\"pages\":\"72-74\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B''lgarska kardiologiia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18087/cardio.2022.5.n1977\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B''lgarska kardiologiia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18087/cardio.2022.5.n1977","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
Metabolic syndrome is a disease the World Health Organization has called a new pandemic of the 21st century. Arterial hypertension is one of the criteria for this diagnosis and a determinant of damage to major target organs. The present clinical case demonstrates an experience of treatment of arterial hypertension associated with metabolic syndrome with a valsartan/sacubitril molecular complex.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
